Ying Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Shi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Yanran Wu
7 shared publicationsGuojing Tao
5 shared publicationsQing Huang
5 shared publicationsShumeng Zhi
Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
5 shared publications- Chunlin Zhuang
The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Naval Medical University/Second Military Medical University, Shanghai, China
4 shared publications Jiaqin Tang
Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
4 shared publications
Latest Publications
- 30 May 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 140, 118716
Discovery of a novel covalent allosteric site CYS434 in Keap1 and its ligand for the treatment of acute lung injury
- 30 May 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 140, 118716
Discovery of a novel covalent allosteric site CYS434 in Keap1 and its ligand for the treatment of acute lung injury
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Discovery of biphenyl-based Keap1–Nrf2 PPI inhibitors through a scaffold hopping strategy: SAR optimization, biological evaluation, and in vivo validation
Acute lung injury (ALI), characterized by excessive inflammation and oxidative stress, remains a severe clinical challenge without effective targeted pharmacological intervention.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Discovery of biphenyl-based Keap1–Nrf2 PPI inhibitors through a scaffold hopping strategy: SAR optimization, biological evaluation, and in vivo validation
Acute lung injury (ALI), characterized by excessive inflammation and oxidative stress, remains a severe clinical challenge without effective targeted pharmacological intervention.
- 12 March 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 159, 108365
Discovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice
- 12 March 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 159, 108365
Discovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice
- Open Access
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 1052-1059
5-(3-(N-(Carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1H-pyrrole-2-carboxylic acid as a Keap1–Nrf2 inhibitor for cerebral ischemia/reperfusion injury treatment
The Keap1 (Kelch-like ECH-Associating Protein 1)–Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2)-ARE (Antioxidant Response Element) signaling pathway plays a crucial role in the oxidative stress response and has been linked to the development and progression of various diseases. Its influence on cerebral ischemia/reperfusion (I/R) injury has garnered significant attention. In our study, we investigated the effect of compound 2, a non-covalent inhibitor of the Keap1–Nrf2 interaction, which was previously discovered by our research group. Specifically, we used 5-(3-(N-(carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1H-pyrrole-2-carboxylic acid (compound 2) to assess its therapeutic potential in a cerebral I/R injury model. The results demonstrated that compound 2 had a significant therapeutic effect, promoting the translocation of Nrf2 from the cytoplasm to the nucleus in diseased tissue. Additionally, it increased the production of key antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH).
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 1052-1059
Open Access5-(3-(N-(Carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1H-pyrrole-2-carboxylic acid as a Keap1–Nrf2 inhibitor for cerebral ischemia/reperfusion injury treatment
The Keap1 (Kelch-like ECH-Associating Protein 1)–Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2)-ARE (Antioxidant Response Element) signaling pathway plays a crucial role in the oxidative stress response and has been linked to the development and progression of various diseases. Its influence on cerebral ischemia/reperfusion (I/R) injury has garnered significant attention. In our study, we investigated the effect of compound 2, a non-covalent inhibitor of the Keap1–Nrf2 interaction, which was previously discovered by our research group. Specifically, we used 5-(3-(N-(carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1H-pyrrole-2-carboxylic acid (compound 2) to assess its therapeutic potential in a cerebral I/R injury model. The results demonstrated that compound 2 had a significant therapeutic effect, promoting the translocation of Nrf2 from the cytoplasm to the nucleus in diseased tissue. Additionally, it increased the production of key antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH).
- 31 August 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107741
Discovery of novel 5-phenyl-1H-pyrrole-2-carboxylic acids as Keap1-Nrf2 inhibitors for acute lung injury treatment
- 31 August 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107741
Discovery of novel 5-phenyl-1H-pyrrole-2-carboxylic acids as Keap1-Nrf2 inhibitors for acute lung injury treatment
- 8 March 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116304
Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy
- 8 March 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116304
Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy
- 28 November 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (1) , 158-171
Diallyl trisulfide inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung cancer via modulating gut microbiota and the PPARγ/NF-κB pathway
DATS ameliorated NNK-induced lung tumorigenesis by the modulation of gut microbiota and regulation of the PPARγ/NF-κB signaling pathway, thereby reducing the accumulation of inflammatory factors.
- 28 November 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (1) , 158-171
Diallyl trisulfide inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung cancer via modulating gut microbiota and the PPARγ/NF-κB pathway
DATS ameliorated NNK-induced lung tumorigenesis by the modulation of gut microbiota and regulation of the PPARγ/NF-κB signaling pathway, thereby reducing the accumulation of inflammatory factors.
- 13 November 2023
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 71 (46) , 17763-17774
Diallyl Disulfide Blocks Cigarette Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced Lung Tumorigenesis via Activation of the Nrf2 Antioxidant System and Suppression of NF-κB Inflammatory Response
Chemoprevention is a potential strategy to reduce lung cancer incidence and death. Recently, we reported that garlic oil significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis. Diallyl disulfide (DADS) is a bioactive ingredient in garlic. Our goal was to examine the chemopreventive effectiveness and mechanism of DADS on NNK-triggered lung cancer in vivo and in vitro in the current investigation. The results indicated that DADS significantly reduced the number of lung nodules in the NNK-induced A/J mice. Consistent with the in vivo results, DADS markedly inhibited NNK-induced decrease of MRC-5 cells' viability. Mechanistically, DADS could promote Nrf2 dissociated from the Keap1-Nrf2 complex and accelerate Nrf2 nuclear translocation, which in turn upregulates its downstream target genes. Besides, DADS further inhibited the NF-κB signaling cascade, thus reducing the accumulation of inflammatory factors. Collectively, these discoveries supported the potential of DADS as a novel candidate for the chemoprevention of tobacco-carcinogen-induced lung cancer.
- 13 November 2023
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 71 (46) , 17763-17774
Diallyl Disulfide Blocks Cigarette Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced Lung Tumorigenesis via Activation of the Nrf2 Antioxidant System and Suppression of NF-κB Inflammatory Response
Chemoprevention is a potential strategy to reduce lung cancer incidence and death. Recently, we reported that garlic oil significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis. Diallyl disulfide (DADS) is a bioactive ingredient in garlic. Our goal was to examine the chemopreventive effectiveness and mechanism of DADS on NNK-triggered lung cancer in vivo and in vitro in the current investigation. The results indicated that DADS significantly reduced the number of lung nodules in the NNK-induced A/J mice. Consistent with the in vivo results, DADS markedly inhibited NNK-induced decrease of MRC-5 cells' viability. Mechanistically, DADS could promote Nrf2 dissociated from the Keap1-Nrf2 complex and accelerate Nrf2 nuclear translocation, which in turn upregulates its downstream target genes. Besides, DADS further inhibited the NF-κB signaling cascade, thus reducing the accumulation of inflammatory factors. Collectively, these discoveries supported the potential of DADS as a novel candidate for the chemoprevention of tobacco-carcinogen-induced lung cancer.